Bio-IT World News
YouTube Facebook LinkedIn TwitterInstagram rss
a-divisiion-of-chi
  • Subscribe
  • News
    • Latest News
    • View Press Releases
    • Post a Press Release
    • Reprint Articles
  • Podcast
  • Advertise
    • Media Kit
    • Digital Advertising
    • Lead Generation
    • Editorial Calendar
    • Webinars
    • Whitepapers
    • Podcasts
    • View Press Releases
    • Post a Press Release
  • Free Downloads
    • Whitepapers
    • Podcasts
    • Webinars
    • Inside eBooks
  • Events
    • Webinars
    • Industry Events
    • IT Conferences
    • Bio-IT World Expo
    • Bio-IT World Expo Europe
  • About Us
    • Editorial Profile
    • Editorial Calender
    • Contact Us
    • Submit a story
    • Innovative Practices Awards
    • Linking Policy
  • Bio-IT World Expo
    • Bio-IT World Boston
    • Bio-IT World Europe
 
 
 
 
  • Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395

    May 24, 2024, 07:39 AM by
    Today, Owkin has unveiled its precision AI drug pipeline in oncology & immunology. To accelerate time-to-patient impact, Owkin has in-licensed OKN4395, a highly selective and potent EP2/4 dual antagonist from Idorsia that will enter Phase 1 trials in early 2025.
    Full story
  • PathAI and Aster Insights Partner to Deliver Combined AI-Derived Structured Pathology and Multimodal Real-World Data Solutions

    May 24, 2024, 07:39 AM by
    PathAI, a global leader in AI-powered pathology, and Aster Insights, the leading provider of scientific and clinical intelligence for oncology discovery, today announced a multi-year strategic partnership to develop curated multimodal datasets that pair PathAI’s PathExplore1 artificial intelligence (AI) tumor microenvironment (TME) quantification panel with Aster Insights’ Avatar clinical, molecular, and digital pathology imaging data. By combining their respective best-in-class platforms, PathAI and Aster Insights will be able to expedite the development of novel insights to accelerate the discovery and development of new treatments for patients with cancer.
    Full story
  • Unraveling the Mysteries of Protein Lipidation with Creative Proteomics

    May 24, 2024, 07:39 AM by
    Full story
  • Qlucore releases unique AI-based solution in the field of lung cancer subtyping

    May 24, 2024, 07:39 AM by
    Qlucore, listed on Nasdaq First North, can now release a new version of Qlucore Insights specifically designed for the lung cancer field, with the capability to classify primary lung samples as well as metastatic lesions. The lung cancer model is being developed with Heidelberg University Hospital, supported by a Eurostars Joint European Programme grant.
    Full story
  • Protheragen-ING Lab, a Trustworthy GLP Service Provider, Unveils Its Cutting-Edge Medical Device Services

    May 23, 2024, 08:10 AM by
    Full story
  • Vaxess Announces $12M in Funding

    May 23, 2024, 08:10 AM by
    Full story
  • Flagship Pioneering Lessons Learned Launching Biotech Startups

    May 23, 2024, 05:00 AM by User Not Found
    Bio-IT World | John Damask is a cloud proponent; he makes no apologies for that. And his experience has mostly been with Amazon Web Services; he is clear on that too. With those disclosures out of the way, Damask offered a “Choose Your Own Adventure”-style tour of cloud best practices and the most common startup cloud mistakes at last month’s Bio-IT World Conference & Expo, letting the audience choose the topics he dug into during the talk.
    Full story
  • CD Formulation Provides Genotoxic Impurity Testing Services to Detect and Evaluate the Potential of GIs for API and Drug Substances

    May 22, 2024, 07:33 AM by
    Full story
  • Reevaluating Data Platforms: The Future of Decentralized Data

    May 22, 2024, 05:00 AM by User Not Found
    Bio-IT World | At the 2024 Bio-IT World Conference & Expo, artificial intelligence (AI) was the main topic stirring up discussions and debates, especially generative AI and its data platforms. Data platforms are crucial tools for AI models, yet there are several barriers that hinder their utilization, efficiency, and accessibility —and none of them are technical or data-related.
    Full story
  • Cresset appoints new Non-Executive Director

    May 21, 2024, 09:10 AM by
    Full story
  • DrFirst Announces 2024 Healthiverse Heroes Award Winners

    May 21, 2024, 09:10 AM by
    DrFirst Announces 2024 Healthiverse Heroes Award Winners https://www.prnewswire.com/news-releases/drfirst-announces-2024-healthiverse-heroes-award-winners-302150945.html?tc=eml_cleartime
    Full story
  • CG Life Acquires Berry & Company Public Relations, Further Expanding Strategic Communications Services for BioPharma and Healthcare

    May 21, 2024, 09:10 AM by
    CG Life, a science-first, tech-enabled agency, acquires Berry & Company Public Relations. The acquisition significantly expands the range of CG Life communications expertise and services to support clients in the biopharma and medical sectors.
    Full story
  • Brain Stimulation Device Could Make Precision Mental Health A Reality

    May 21, 2024, 05:28 AM by User Not Found
    Bio-IT World | In the not-too-distant future, disorders of the brain could be treated with the same precision as heart disease and cancer. The means will be a therapeutic brain-computer interface (BCI) the size of a small blueberry for people suffering from treatment-resistant depression that uses a similar type of implant technology as Elon Musk’s Neuralink for helping paralyzed people speak.
    Full story
  • Huateng Pharma Introduces Piroctone Olamine: A New Solution for Fungal Infections and Dandruff Control

    May 20, 2024, 08:13 AM by
    Huateng Pharma, a leader in innovative pharmaceutical solutions, is excited to announce the launch of its latest product, Piroctone Olamine (CAS No. 68890-66-4).
    Full story
  • Biopharma PEG to Showcase Innovative PEG Derivatives at BIO 2024 in San Diego

    May 20, 2024, 08:13 AM by
    Biopharma PEG, a renowned leader in the development and supply of high-quality polyethylene glycol (PEG) derivatives, is pleased to announce its participation in the BIO International Convention 2024. The event will take place from June 3-6, 2024, at the San Diego Convention Center, and attendees can visit Biopharma PEG at Booth 5102.
    Full story
  • Lindus Health Announces Cosmetics Clinical Trial with Acinonyx Bio to Evaluate an Alternative to Benzoyl Peroxide for Inflammatory Acne

    May 17, 2024, 07:46 AM by
    https://www.prnewswire.com/news-releases/lindus-health-announces-cosmetics-clinical-trial-with-acinonyx-bio-to-evaluate-an-alternative-to-benzoyl-peroxide-for-inflammatory-acne-302146936.html?tc=eml_cleartime
    Full story
  • Phenomix Sciences Raises $7.8M in Funding to Accelerate Adoption of Obesity Precision Medicine

    May 17, 2024, 07:46 AM by
    Precision medicine biotechnology company for obesity secures additional institutional capital from prominent industry leaders to expand the use of its novel phenotyping test and advance clinical research in weight loss treatment.
    Full story
  • IntelliGuard Appoints Seasoned Leader as New Chief Product Officer for Enhanced Healthcare Solutions

    May 17, 2024, 07:46 AM by
    Rob Sobie to support IntelliGuard’s ongoing innovation to track, trace, and improve safety in medication inventory
    Full story
  • MDClone Earns Fourth Consecutive "Best Healthcare Big Data Platform" Award from MedTech Breakthrough

    May 17, 2024, 07:46 AM by
    https://www.prnewswire.com/news-releases/mdclone-earns-fourth-consecutive-best-healthcare-big-data-platform-award-from-medtech-breakthrough-302147956.html?tc=eml_cleartime
    Full story
  • Prebiotic Fibre Supplement Significantly Reduces Risk of Developing Type 2 Diabetes, UK Study Finds

    May 17, 2024, 07:46 AM by
    Today, The British Journal of Nutrition published a study that found the consumption of a daily prebiotic fibre supplement helped to improve insulin sensitivity and other important health markers in patients with pre-diabetes
    Full story
  • «
  • 31
  • 32 (current)
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • »
 
CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Healthcare

IT, AI, ML & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

Venture, Innovation & Partnering

CHI Divisions

Conferences

Reports & Market Research

Barnett Educational Services

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers


Request Information

Privacy Policy